• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Kronos Bio Inc. (Amendment)

    2/9/23 11:25:08 AM ET
    $KRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRON alert in real time by email
    SC 13G/A 1 tv01262-kronosbioinc.htm SCHEDULE 13G/A kronosbioinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Kronos Bio Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  50107A104

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  50107A104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    20,653

    7.  SOLE DISPOSITIVE POWER

    1,470,712

    8.  SHARED DISPOSITIVE POWER

    34,210

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,504,922

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    2.64%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Kronos Bio Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1300 So. El Camino Real, Suite 300
    San Mateo, CA 94402

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    50107A104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $KRON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRON

    DatePrice TargetRatingAnalyst
    11/14/2024$6.00 → $1.00Overweight → Neutral
    Piper Sandler
    11/14/2024Buy → Hold
    TD Cowen
    9/14/2022$12.00Buy
    Berenberg
    2/28/2022$50.00 → $30.00Overweight
    Piper Sandler
    11/10/2021$35.00 → $36.00Buy
    HC Wainwright & Co.
    10/20/2021Outperform
    Cowen
    6/24/2021$35.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $KRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kronos Bio Inc.

      SC 13G/A - Kronos Bio, Inc. (0001741830) (Subject)

      11/14/24 7:58:27 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Kronos Bio Inc.

      SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)

      7/2/24 9:01:03 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Kronos Bio Inc.

      SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)

      6/12/24 7:32:56 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kronos downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Kronos from Overweight to Neutral and set a new price target of $1.00 from $6.00 previously

      11/14/24 7:43:21 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos downgraded by TD Cowen

      TD Cowen downgraded Kronos from Buy to Hold

      11/14/24 7:42:59 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on Kronos with a new price target

      Berenberg initiated coverage of Kronos with a rating of Buy and set a new price target of $12.00

      9/14/22 7:25:57 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    SEC Filings

    See more
    • SEC Form SC 14D9 filed by Kronos Bio Inc.

      SC 14D9 - Kronos Bio, Inc. (0001741830) (Subject)

      5/15/25 1:09:14 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Kronos Bio Inc.

      10-Q - Kronos Bio, Inc. (0001741830) (Filer)

      5/8/25 4:21:04 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC14D9C filed by Kronos Bio Inc.

      SC14D9C - Kronos Bio, Inc. (0001741830) (Subject)

      5/1/25 9:22:44 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Administrative Officer Frisbee Allison

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      10/15/24 6:57:17 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Lin Charles Y

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      10/15/24 6:55:36 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT & CEO Bischofberger Norbert W bought $733,801 worth of shares (615,518 units at $1.19) (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      7/1/24 8:27:32 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Financials

    Live finance-specific insights

    See more
    • Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

      Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4 neutropenia, dose proportional exposure, dose-dependent target engagement, and 24-hour plasma half-life Dose escalation continues; dosing of patients at the 80 mg dose level is ongoing Enrollment ongoing in dose expansion phase in MYC-dependent and other transcriptionally addicted solid tumors, including lung, ovarian, and triple negative breast cancers Company to host conference call and webcast today at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D.

      10/13/23 12:30:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

      SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., followed by a Q&A session. The event will feature trial investigator, Miguel Villalona-Calero, M.D, Medical Oncologist and Director of Early Therapeutics, City of Hope, along with Kronos Bio management, who will discuss the current treatment landscape for patients with MYC-dependent solid tumors, provide an overview of KB-0742 and further discuss the poster to be presented at the AACR-NCI-EORTC Interna

      10/4/23 4:05:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

      Company to discontinue Phase 3 entospletinib trial for strategic reasons Enrollment continues for Phase 1/2b trial in relapsed/refractory AML with Kronos Bio's next generation SYK inhibitor, lanraplenib Company on track to provide KB-0742 update from ongoing Phase 1/2 clinical trial in Q4 With $270.3 million in cash, cash equivalents and investments as of Sept. 30, 2022, Kronos Bio extends expected cash runway from Q4 2024 into Q2 2025 Conference call and webcast scheduled for today at 4:30 p.m. ET SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today

      11/8/22 4:05:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (NASDAQ:KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ( "Concentra"), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock ("Kronos Bio Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 50% of the net proceeds in the case of a disposition of the Company's product ca

      5/1/25 8:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results. Fourth Quarter and Full Year 2024 Financial Results Cash, cash equivalents and investments: Cash, cash equivalents and investments as of December 31, 2024, were $112.4 million.R&D Expenses: Research and development expenses were $8.4 million for the fourth quarter of 2024, which includes non-cash stock-based compensation expense of $0.7 million. For the full year of 2024, research and development expenses were $48.7 million, which includes non-cash stock-based compensation expense o

      3/18/25 4:01:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Announces CEO Transition and Reduction in Force

      – Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that its Board of Directors has appointed Deborah Knobelman, Ph.D., as President and Interim Chief Executive Officer, effective December 3, 2024. Dr. Knobelman will be the principal executive, financial and accounting officer. She is succeeding Norbert Bischofberger, Ph.D., who will step dow

      11/27/24 7:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT & CEO Bischofberger Norbert W bought $733,801 worth of shares (615,518 units at $1.19) (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      7/1/24 8:27:32 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT & CEO Bischofberger Norbert W bought $3,119,081 worth of shares (3,005,122 units at $1.04) (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      6/12/24 7:23:55 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bischofberger Norbert W bought $1,470,395 worth of shares (1,731,056 units at $0.85), increasing direct ownership by 214% to 2,540,665 units (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      11/17/23 5:41:27 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Leadership Updates

    Live Leadership Updates

    See more
    • Kronos Bio Announces CEO Transition and Reduction in Force

      – Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that its Board of Directors has appointed Deborah Knobelman, Ph.D., as President and Interim Chief Executive Officer, effective December 3, 2024. Dr. Knobelman will be the principal executive, financial and accounting officer. She is succeeding Norbert Bischofberger, Ph.D., who will step dow

      11/27/24 7:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

      SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions. "I'm excited to have Deb join our team. She is a proven life sciences leader, and her strategic vision will play a critical role in shaping the future of Kronos Bio. As we continue to

      5/21/24 8:15:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments